Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine

J Virol. 2023 Nov 30;97(11):e0077123. doi: 10.1128/jvi.00771-23. Epub 2023 Oct 30.


Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine.

Keywords: Fc-effector functions; functional antibodies; respiratory syncytial virus; vaccines.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II

MeSH terms

  • Aged
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Humans
  • Immunoglobulin Fc Fragments
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus Vaccines* / immunology
  • Respiratory Syncytial Virus, Human
  • Viral Fusion Proteins / immunology


  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin Fc Fragments
  • Respiratory Syncytial Virus Vaccines
  • Viral Fusion Proteins

Grants and funding